Shots:

• Grünenthal to acquire EU rights (Ex- Spain and the UK) of Crestor & its associated brands for ~$350M and will take over bulk production and packaging by 2025. The deal is expected to be closed in Q1’21
• The payments will be made in two tranches: $320M will be paid upon transaction closing and $30M as additional milestones
• Crestor is a statin- a lipid-lowering agent used to treat blood-lipid disorders & to prevent CV events- such as heart attacks & strokes- and is approved as a lipid-regulating medicine in 100+ countries

 ­ Ref: PRNewswire | Image: The Scientist Magazine